{
  "docId": "019de076-8cfe-74f8-8267-71bfaaa75a6b",
  "docSlug": "6f650cb16e144ff2cbcc39c10e5d03e1",
  "documentTitle": "23andMe | Investor Presentation Deck | 39 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 39,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to present pharmacology, mechanism of action (diagram), and clinical development status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8cfe-74f8-8267-71bfaaa75a6b/24",
  "deckHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b",
  "deckJsonHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b.json",
  "deckAnchorHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "'610 Activates T-cell Function by Blocking the CD200R1 Checkpoint",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0f1c47f-f41c-45d0-84d6-4c2f90a8cdfb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "list",
      "text": "'610 Clinical Development*: Well tolerated up to 1400 mg, PK supports Q3W, Promising therapeutic index, Monotherapy dev ongoing, Indication CDPs and TPPs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "615fd40a-ca54-45a7-bed2-136dc8cce36f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "'610 Primary Pharmacology*: Subnanomolar affinity, Kills tumor cells in vitro, Anti-tumor activity in vivo, Potential for monotherapy, Potential for combination",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fea6d5d2-eae4-40f2-b34b-fa6c08230f54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*PMID: 37288324; *CD200-expressing cell types include tumor, stroma and endothelial; *Rasco, et al., 2023, SITC Annual Meeting #619; Glatt, et al., 2023 SITC Annual Meeting #609",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23687e60-bcbf-4d8e-b609-788875bc8f2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.05
      },
      "kind": "title",
      "text": "23ME-00610 ('610), a Fully Humanized, Effectorless IgG1, Inhibits Immunosuppressive Signaling via High Affinity Binding to CD200R1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e8c82cf-5643-4cf5-a394-bc4cd03b55d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 9,
      "beatId": "93eec936-fceb-4bb2-ab9b-6265df978407",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-39 present 23andMe's solution, including their therapeutic pipeline and approach",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "222f1e4a-2305-4ee1-bc08-b05e43ea38f6",
      "evidence": "Slides 23-26 emphasize the importance of addressing unmet medical need in oncology",
      "position": 1,
      "objective": "Highlight the cost of inaction in addressing unmet medical need",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}